Pharsight

Drugs that contain Dantrolene Sodium

1. Ryanodex patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9884044 EAGLE PHARMS Treatment using dantrolene
Jun, 2022

(1 year, 10 months ago)

US8604072 EAGLE PHARMS Treatment using dantrolene
Jul, 2022

(1 year, 9 months ago)

US8110225 EAGLE PHARMS Treatment using dantrolene
Dec, 2022

(1 year, 3 months ago)

US8685460 EAGLE PHARMS Treatment using dantrolene
Feb, 2023

(1 year, 2 months ago)

US7758890 EAGLE PHARMS Treatment using dantrolene
Jun, 2025

(1 year, 2 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Jul 22, 2021
Orphan Drug Exclusivity(ODE-69) Jul 22, 2021

Market Authorisation Date: 22 July, 2014

Treatment: For use in the treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk.

Dosage: FOR SUSPENSION;INTRAVENOUS

More Information on Dosage

RYANODEX family patents

Family Patents